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Abstract Surface of detonation nanodiamonds was
functionalized for the covalent attachment of immuno-
globulin, and simultaneously bovine serum albumin and
Rabbit Anti-Mouse Antibody. The nanodiamond-IgG
I125
and RAM-nanodiamond-BSA
I125 complexes are stable in
blood serum and the immobilized proteins retain their
biological activity. It was shown that the RAM-nanodia-
mond-BSA
I125 complex is able to bind to the target antigen
immobilized on the Sepharose 6B matrix through anti-
body–antigen interaction. The idea can be extended to use
nanodiamonds as carriers for delivery of bioactive sub-
stances (i.e., drugs) to various targets in vivo.
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Introduction
Recently, much attention has been drawn to the studies on
developing systems for address delivery of diagnostic and
therapeutic agents to biological targets. For these purposes,
liposomes [1, 2] and various polymers [3, 4] are known
examples. Other carriers such as nanoparticles of metals
[5–7] and nanotubes [8] represent an attractive alternative.
It is obvious that such systems must contain a ligand
exhibiting high selectivity and afﬁnity towards a biological
target to which they carry the desired substance. For
example, antibodies are often used as targeting agents [9].
Detonation nanodiamonds with a high colloidal stability
in aqueous and non-aqueous media are a promising mate-
rial for the targeted delivery of substances [10–12]. Earlier
studies have shown that the nanodiamonds effectively
adsorb various biomolecules [13–17], allow obtaining
sterile hydrosols for all types of injections including
intravenous ones [18] and show a high biocompatibility in
vivo [19, 20].
In this work, we investigated the possibility of conju-
gating nanodiamonds with iodine-125 labeled immuno-
globulin (IgG
I125) and bovine serum albumin (BSA
I125),
and Rabbit Anti-Mouse Antibody (RAM), as well as
properties of the obtained complexes.
Experimental Details
A nanodiamond powder produced at Krasnoyarsk Research
Centre with aggregate sizes varying in the range
30–125 nm was modiﬁed to impart a high colloidal sta-
bility in hydrosols. The modiﬁcation method, physical and
chemical properties of the nanodiamonds have been
described elsewhere [10, 11]. Nanodiamond hydrosols
were prepared using DI water with concentration of the
dispersed phase 15.0 g l
-1. Milli-Q system (Millipore,
USA) was used for producing DI water.
Mouse immunoglobulin G (IgG) (Medix Biochemical,
Finland); bovine blood serum (Mikrogen, Russia); BSA
(Amersham, England); Sepharose 6B (Pharmacia, Swe-
den); Rabbit AntiMouse Antibody (RAM) (Imtek Ltd.,
Russia); NaI
125 (RITVERC, Russia); chloramine-T and
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I125 were produced as follows. A
chloramine-T solution (10 ll) at concentration of
2.5 mg ml
-1 and NaI
125 solution (40 ll) of total activity
*20 MBk were added to IgG (or BSA) solution (50 ll) at
a protein concentration of 1 mg ml
-1 in 0.5 M phosphate
buffer (pH 7.0). The samples were stirred and incubated at
room temperature for 2 min. Then, a sodium metab-
isulphite solution (100 ll) at concentration of 5 mg ml
-1
was added to the samples. Unbound radioactive marker
(I
125) was removed by chromatography on a mini-column
with Sepharose 6B (8 9 20 mm) at eluent ﬂow rate of
1 ml/min, with 0.5 M phosphate buffer (pH 7.0). A fraction
containing protein IgG
I125 (or BSA
I125) was collected at the
column output, and its total radioactivity was evaluated
using gamma-counter ‘‘NK-Narkotest’’ (VNIIMP, Russia).
Adsorption of IgG
I125 on the nanodiamonds particles
was performed in the following way. A radioactive protein
solution was mixed with the nanodiamond hydrosol (pro-
tein-to-nanodiamond ratio—1:10 (w/w)). The suspension
obtained was incubated during 1 h at room temperature and
stirred continually throughout the incubation. Nanodia-
monds with the adsorbed protein were collected by cen-
trifugation at 16,000g for 5 min at 20 C. The supernatant
was taken from sample and its residual radioactivity was
measured to evaluate the amount of non-adsorbed protein.
The precipitate was repeatedly washed with the PBS-buffer
to remove the unbound protein, every time re-suspending
the nanoparticles in a fresh buffer, collecting them by
centrifugation under the above-mentioned conditions and
taking a supernatant for radioactivity evaluation.
For immobilization of IgG
J125, the surface of nanodia-
monds was chemically activated with p-benzoquinone
(vide infra)—a well-known method used for covalent
coupling of enzymes to carriers [21, 22]. For this, phos-
phate buffer, 20 mM, pH 8.0 and 100 mg of hydroquinone
dissolved in aqueous ethanol were consequently added with
stirring to 5 ml of 1.5 wt% nanodiamond hydrosol. The
suspension was incubated for 2 h at room temperature,
washed with DI water followed by thorough washing with
1 M NaCl and rinsing with DI water.
Immobilization of the radioactive protein was carried
out in 100 mM Na-bicarbonate buffer (pH 8.0). For these
purposes, IgG
I125 solution was mixed with the modiﬁed
nanodiamond hydrosol (protein-to-nanodiamond ratio—
1:10 (w/w)). The suspension obtained was incubated at
continual stirring for overnight at 4 C. Nanodiamonds
with the immobilized protein were collected by centrifu-
gation at 16,000g for 5 min at 20 C. The supernatant was
taken from sample, and the amount of non-immobilized
protein was determined by its residual radioactivity. The
precipitate of nanodiamonds was repeatedly washed with
the PBS-buffer to remove the unbound proteins. Simulta-
neous covalent immobilization of the two proteins (RAM
and BSA
I125) on the nanodiamonds was performed in the
same manner.
Evaluation of the stability of these complexes in blood
serum included two stages. At ﬁrst, nanodiamond pre-
cipitates containing the adsorbed or immobilized IgG
I125
preliminarily washed with PBS-buffer were treated with
serum as follows. The precipitates were re-suspended in
serum, incubated for 5 min at 20 C and then the parti-
cles were collected by centrifugation at 16,000g for
5 min at 20 C. Supernatants were taken from samples
and their residual radioactivities were measured. The
treatment was performed repeatedly, each time suspend-
ing the particles in a fresh serum, incubating and col-
lecting them by centrifugation. The residual radioactivity
was measured after each centrifugation. At the second
stage, chromatography of the obtained supernatants was
carried out on the column with Sepharose 6B
(10 9 200 mm) equilibrated with 150 mM NaCl at elu-
ent ﬂow rate 1 ml/min and fractions of 0.5 ml were
collected. Thereafter, we evaluated the radioactivity of all
fractions obtained after chromatography. The same
method was used to determine the stability of the RAM–
nanodiamond–BSA
I125 complex.
Sedimentation stability of the nanodiamond-IgG
I125 and
RAM-nanodiamond-BSA
I125 complexes obtained after
covalent immobilization of proteins was evaluated as fol-
lows. After immobilization of IgG
I125 (or RAM and
BSA
I125), unbound proteins were removed by chromatog-
raphy on the column with Sepharose 6B (10 9 200 mm)
equilibrated with 150 mM NaCl at eluent ﬂow rate 1 ml/
min. Total fraction containing the nanodiamond–IgG
I125
(or RAM–nanodiamond–BSA
I125) complex was blended
with blood serum. The mixture was placed in an ice bath
and sonicated at 22 kHz (six times for 10 s, with 20 s
intervals). After that, samples of 1 ml were collected and
centrifuged at 16,000g and 20 C. The time of centrifu-
gation was individually selected for each sample. The
residual radioactivity of supernatants obtained by centri-
fugation was measured.
Speciﬁc interaction of the RAM–nanodiamond–BSA
I125
complex with a target antigen was analyzed in the fol-
lowing way. A sample of blood serum containing the
RAM–nanodiamond–BSA
I125 complex was produced
using the method described in the previous paragraph. Two
portions of this sample (1 ml each) were loaded into two
mini-columns packed with 1 ml of Sepharose 6B. A con-
trol column contained the adsorbent with the immobilized
BSA, while an experimental column contained the adsor-
bent with the immobilized mouse IgG. Each column was
washed with 5 ml of serum, and the residual radioactivity
of the washed adsorbents was evaluated.




by Adsorption of Protein
The results evidenced that IgG
I125 is effectively adsorbed
by nanodiamonds under the chosen conditions. After
incubation with protein and removal of the particles by
centrifugation, not more than 25–28% of the initial radio-
activity of protein preparations was registered in superna-
tants. Multiple washing of the nanoparticles with adsorbed
IgG
I125 in PBS-buffer did not lead to desorption of protein.
After the ﬁrst two washings, supernatants display about
0.5–1% of the initial radioactivity. At the following
washings, the level of radioactivity registered in superna-
tants did not exceed 0.1%. At the same time, it has been
found that the obtained nanodiamond–IgG
I125 complexes
were not stable in blood serum. Repeated washings of
precipitates with serum resulted in almost total desorption
of IgG
I125 (Fig. 1).
Protein desorption was also conﬁrmed by analyzing the
radioactivity of fractions obtained by the chromatography
of supernatants. Results show (Fig. 2) that supernatants
contained a signiﬁcant amount of free IgG
I125 (main peak
of radioactivity—fractions 10–28) and a small amount of
nanodiamonds with adsorbed proteins, which could not be
removed by centrifugation (minor peak of radioactivity—
fractions 5–7).
It should be noted that the main radioactive peak
observed after chromatography of the supernatant (Fig. 2)
completely corresponds to the radioactive peak observed
after chromatography of the initial protein IgG
I125 sample
(Fig. 3). At chromatography of a serum sample with
re-suspended nanoparticles after 20 washings (Fig. 1), one
can observe a radioactivity distribution (Fig. 4) that is
different to that at the chromatography of supernatants
(Fig. 2).
In this case, the ﬁrst radioactive peak (fractions 4–8)
accounts for about 75% of the total radioactivity, which
indicates the presence of the nanodiamond–IgG
I125 com-
plex. The second peak (fractions 12–28) amounting to
about 25% of the total radioactivity bears evidence of a
signiﬁcant amount of desorbed (free) protein presented
within the sample. Upon combining the fractions 4–8 (the
ﬁrst peak) and subsequent chromatography, the distribution
of radioactivity was similar to that shown in Fig. 4.
In general, the experimental data obtained in this study
show that it is impossible to get nanodiamond-IgG
I125
complexes stable in blood serum by nonspeciﬁc adsorbing
the protein molecules on the nanoparticles.
Fig. 1 Radioactivity of supernatants after multiple washings with
serum of a precipitate containing IgG
I125 adsorbed on nanodiamonds
(percentage of radioactivity of the initial protein IgGI
I125 sample)
Fig. 2 Typical distribution of radioactivity registered after Sepharose
6B chromatography of supernatants. The supernatants were obtained
by washings with serum of the precipitate containing IgG
I125
adsorbed on nanodiamonds
Fig. 3 Distribution of radioactivity registered after Sepharose 6B
chromatography of the initial protein IgG
I125 sample
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I125 Complex Produced by Covalent
Immobilization of Protein
The surface of detonation nanodiamond particles is cov-
ered with variety of functional groups, which originate
from synthesis and puriﬁcation processes. Among them, a
hydroxyl group (–OH) is one of the most abundant [23].
This group was involved in a procedure for covalent cou-
pling of IgG onto the nanodiamonds by treating the
nanoparticles with benzoquinone, which is well known to
provide chemical activation of hydroxyl containing sur-
faces [21]. The thus activated nanoparticles readily react
with an amine group of the protein molecules. The reaction
sequence of the benzoquinone activation and biochemical
coupling is presented on Fig. 5.
Experiments showed the efﬁciency of covalent immo-
bilization of IgG
I125 on the surface of modiﬁed nanodia-
monds. After incubation with protein and removal of the
particles by centrifugation, not more than 25–30% of initial
radioactivity of protein preparations was registered in
supernatants. Like in protein adsorption (see above), serial
washing of the immobilized IgG
I125 with the PBS-buffer
did not lead to desorption of the protein. The radioactivity
level registered in the washings after removal of the par-
ticles was the same as in the previously described experi-
ment—about 0.5–0.8% after the ﬁrst two washings and less
than 0.1% after the following washings. After the nano-
particles with immobilized protein were repeatedly washed
with blood serum a signiﬁcant level of radioactivity was
registered in supernatants as well (Fig. 6).
It would seem that these data indicate the instability of
the nanodiamond-IgG
I125 complex in serum. However, the
radioactivity of fractions after chromatography of super-
natants showed a radically different result. As shown in
Fig. 7, only a single peak (fractions 4–8) is observed,
which accounts for almost all radioactivity (*98%) and
corresponds to the peak of the radioactive nanodiamond-
IgG
I125 complex.
At chromatography of a serum sample with nanoparti-
cles washed 20 times with serum (Fig. 5), the observed
radioactivity distribution (Fig. 8) was similar to that at the
chromatography of supernatants.
These results allow a conclusion that the nanodiamond–
IgG
I125 complex obtained via the covalent attachment of
protein is not just stable, but displays a high resistance to
sedimentation in blood serum. This conclusion is con-
ﬁrmed with the tests on sedimentation of the complex in
serum at centrifugation in a wide time interval. About 50%
of the initial radioactivity was recorded in supernatants
even after centrifuging a serum sample containing the
nanodiamond–IgG
I125 complex at 16,000g for 1 h (Fig. 9).
RAM–Nanodiamond–BSA
I125 Complex Obtained
by Simultaneous Covalent Immobilization
of Two Types of Proteins
The design of drug delivery systems on the base of par-
ticulate carriers must take into account the fact that after
being immobilized on the carrier surface, ligand molecules
should preserve their ability to bind to the target receptor
molecule. It is known that immobilization by means of
chemical attachment may result in a reduction in speciﬁc
activity of a ligand (e.g., protein) and sometimes in its total
deactivation [24]. We have investigated the possibility to
design a model delivery system on the base of nanodia-
monds. For this purpose, two types of proteins were
simultaneously covalently immobilized on the nanoparti-
cles—RAM, speciﬁcally interacting with a mouse IgG and
serving as a ligand, and BSA
I125 serving as a radioactive
marker (Fig. 10). The results of the experiment showed
that the RAM–nanodiamond–BSA
I125 complex exhibits
sustainability and high colloidal stability in blood serum as
well as the nanodiamond–IgG
I125.
Fig. 4 Distribution of radioactivity registered after Sepharose 6B
chromatography of a serum sample containing IgG
I125 on nanodia-
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123Chromatography of serum samples containing the
RAM–nanodiamond–BSA
I125 complex using mini-col-
umns Sepharose 6B with immobilized BSA (control) and
mouse IgG (experimental) revealed that the complex is
able to speciﬁcally bind to the target antigen. Once chro-
matography was performed and columns were washed, the
radioactivity registered in the sorbent with immobilized
mouse IgG signiﬁcantly (more than nine times) exceeded
that of the sorbent with immobilized BSA (Fig. 11).
The experimental data obtained in this study show that
the ligand molecules (RAM) preserve their speciﬁc activity
after covalent immobilization on the nanodiamonds and are
able to attach to the target receptor molecules (mouse IgG).
This at least was demonstrated by experiments in vitro.
Fig. 6 Radioactivity of supernatants after serial washings of the
precipitate containing IgG
I125 immobilized on nanodiamonds with
serum (percentage of radioactivity of the initial protein IgG
I125
sample)
Fig. 7 Typical distribution of radioactivity registered after Sepharose
6B chromatography of supernatants. The supernatants were obtained
by washing the precipitate containing IgG
I125 immobilized on
nanodiamonds with serum
Fig. 8 Distribution of radioactivity registered after Sepharose 6B
chromatography of a serum sample containing IgG
I125 immobilized
on nanodiamonds. The sample was obtained after 20 washings
Fig. 9 Residual radioactivity of supernatants versus time of centri-
fugation at 16,000g for serum samples containing the nanodiamond–
IgG
I125 complex
Fig. 10 Schematic of experiment to illustrate the ability of the
RAM–nanodiamond–BSA
I125 complex to bind to the target antigen
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Thus, this study shows the possibility of applying detona-
tion nanodiamonds with a high colloidal stability in




experiments showed that it is impossible to receive nan-
odiamond–IgG
I125 complexes possessing stability in blood
serum by non-speciﬁc absorption of the protein molecules
on nanoparticles. However, in vitro experiments proved
that complexes obtained by covalent immobilization of
IgG
I125 or simultaneous immobilization of RAM and
BSA
I125 demonstrate sustainability and high colloidal sta-
bility in blood serum. It was further demonstrated that a
complex obtained by simultaneous covalent immobiliza-
tion of RAM and BSA
I125 on the nanoparticles is able to
speciﬁcally bind to the target antigen (mouse IgG). The
obtained results allow one to consider the possibility of
applying nanodiamonds as carriers for address deliveries of
bioactive substances (i.e., drugs) to various biological tar-
gets in vivo.
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